Thrombospondin 1 (TSP1) is a matricellular glycoprotein that can be secreted by many cell types. Through binding to extracellular proteins and/or cell surface receptors, TSP1 modulates a variety of cellular functions. Since its discovery in 1971, TSP1 has been found to play important roles in multiple biological processes including angiogenesis, apoptosis, latent transforming growth factor-β activation, and immune regulation. Thrombospondin 1 is also involved in regulating many organ functions. However, the role of TSP1 in liver diseases has not been extensively addressed. In this review, we summarize the findings about the possible role that TSP1 plays in chronic liver diseases focusing on non-alcoholic fatty liver diseases, liver fibrosis, and hepatocellular carcinoma.
INTRODUCTION
T HROMBOSPONDINS ARE A family of secreted multifunctional proteins consisting of thrombospondin 1-5. Thrombospondin 1 (TSP1) was the first member of the family to be discovered, in 1971. Thrombospondin 1 is a homotrimeric glycoprotein of 450 kDa with multiple functional domains. [1] [2] [3] [4] [5] The structure of TSP1 is composed of three polypeptide chains, which are connected by disulfide bonds. 6 This structure is comprised of different regions that are beneficial to the overall function of this extracellular protein (Fig. 1) . The amino-terminal domain of TSP1 plays a role in heparin binding that regulates both removal and uptake of TSP1. 7 It also regulates cell adhesion and chemotaxis. The procollagen region is involved in angiogenesis suppression. 2 There are then three repeats (types I, II, and III). These repeats play a role in cellular adhesion, migration, growth, and angiogenesis. 2, 6 The final region of TSP1 is the carboxy-terminal domain. This domain plays a role in cell adhesion, migration, platelet accumulation, and regulating nitric oxide signaling. 2, 6, 8 In many cell types, TSP1 is secreted to extracellular space, where it can bind to many receptors (e.g. integrins, CD36, and CD47) and elicits cellular functions. CD36 is one of TSP1's receptors. It exists on many cell types such as endothelial cells, vascular smooth muscle cells, adipocytes, macrophages, tubular cells, and podocytes. [9] [10] [11] CD36 interacts with the type 1 repeats of TSP1 to regulate cellular functions in many ways. It activates the p38 mitogen-activated protein kinase (MAPK) pathway and induces endothelial cell apoptosis, which negatively regulates angiogenesis.
12-14 Thrombospondin 1 and CD36 interaction also activates the p38 MAPK pathway in kidney podocytes and is involved in podocyte apoptosis. 11 On macrophages, TSP1 binds to CD36 and leads to macrophage activation. 10 In platelets, TSP1 activates CD36-dependent pathways including c-Jun N-terminal kinase and p38 MAPK and regulates platelet functions. 15 In addition to CD36, CD47 is another receptor for TSP1. CD47 expresses on many cell types including endothelial cells, smooth muscle cells, epithelial cells, neutrophils, erythrocytes, and chondrocytes. 16, 17 CD47 activation by the Cterminal domain of TSP1 suppresses intracellular nitric oxide and downstream cyclic guanosine monophosphate (cGMP) signaling, 18, 19 which are dependent on endothelial nitric oxide synthase activation. In addition, effects of CD47 activation contribute to elevated reactive oxidative species in a number of tissues, including kidneys. 20 Through these interactions, CD47 regulates inflammation, cell adhesion, and survival in response to various stressors. 16, 17, 21 Thrombospondin 1 has been shown to play a role in many diseases. For example, our studies and others have shown that TSP1 is a major regulator for latent transforming growth factor-β (TGF-β) activation and contributes to the development of diabetic nephropathy. [22] [23] [24] [25] We found that high glucose treatment (to mimic diabetes) stimulates TSP1 expression in kidney mesangial cells through decreased cGMP/cGMP-dependent protein kinase pathway-mediated transcriptional suppression and increased expression of transcription factor upstream stimulatory factor 2. 24, 26 Increased TSP1 can then activate latent TGF-β. This activation is through binding of the KRFK sequence in the type 1 repeats domain of TSP1 to the LSKL sequence of latency-associated peptide from the latent TGF-β. 27 The activated TGF-β further stimulates mesangial cell to produce excessive amount of extracellular matrix (ECM) protein in the kidney such as collagen IV, leading to kidney fibrosis. In addition, TSP1 plays a role in organ ischemia reperfusion injury. 19, 28, 29 Recent studies have reported that TSP1 inhibits renal tubular epithelial cell recovery after ischemia reperfusion injury through inhibition of proliferation/self-renewal in a CD47-dependent manner. 30 Thrombospondin 1 also plays a role in cancer metastasis 31 and inflammation 10, 32, 33 in a CD36-dependent pathway. Taken together, the role of this extracellular protein in disease is widespread; it is also clinically significant in terms of hepatic function. Therefore, in this review, we focus on TSP1 and its role in chronic liver diseases.
EXPRESSION OF TSP1 IN LIVER
P LATELETS ARE A major source of TSP1 in mammals, which can rapidly release TSP1 from their α-granules after activation. Thrombospondin 1 can also be produced by many types of cells including hepatocytes, stellate cells, megakaryocytes, vascular smooth muscle cells, fibroblasts, endothelial cells, epithelial cells, and keratinocytes. 7, 18, [34] [35] [36] [37] [38] In the liver, during murine embryogenesis, megakaryocytes are the sources of TSP1 transcripts in this organ detected as early as day 12.
High steady-state levels of mRNA of TSP1 were observed on days 11-13, with a significant decrease thereafter, as shown by using RNase protection assays. 39 In adult liver, TSP1 is expressed at very low or nearly undetectable levels under physiological conditions. 40 However, TSP1 can be markedly upregulated under pathophysiological conditions in the liver. For example, hepatocytes and endothelial cells from normal liver tissue showed minimal staining for TSP1, whereas hepatocytes from liver tissue of patients with congenital hepatic fibrosis showed stronger staining for TSP1 than normal tissue. 41 Congenital hepatic fibrosis-derived stellate cells also secrete more TSP1. 41 In an in vitro model of non-alcoholic fatty liver disease (NAFLD), free fatty acid-treated hepatocytes had increased intracellular lipid accumulation, associated with increased pro-inflammatory cytokines and TSP1 expression. 42 In a partial hepatectomy mouse model, immediate and transient TSP1 expression was induced, predominantly from endothelial cells and activated hepatic stellate cells (HSCs). 43 Expression of TSP1 was also increased in stellate cells isolated from alcohol-treated rats or in liver from carbon tetrachloride or 3,5-diethoxycarbonyl-1,4-dihydrocollidine dietinduced fibrosis mouse models. 44 Importantly, in liver samples from human patients with alcohol cirrhosis, non-alcoholic steatohepatitis-related cirrhosis, or other fibrosis, TSP1 levels were upregulated. 44 Taken together, these data indicate that, under different pathologic conditions, TSP1 is upregulated in different liver cell types to a varied extent. These data also provide strong 
ROLE OF TSP1 IN NAFLD
W ITH THE EPIDEMIC burden of obesity and metabolic diseases, NAFLD is becoming one of the most common hepatic disease worldwide. 45 Non-alcoholic fatty liver disease is defined histologically as lipid accumulation in no more than 5% of hepatocytes with no evidence of excess alcohol intake, hepatitis B or C infection, autoimmune hepatitis, iron overload, or drug or toxin intake. This is a progressive disease ranging from steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The role of TSP1 in NAFLD is largely unknown.
Thrombospondin 1 is involved in tissue injury and inflammatory diseases such as rheumatoid arthritis and inflammatory joint disease. [46] [47] [48] [49] [50] [51] [52] [53] Recently, TSP1 was identified as an adipokine that is upregulated in visceral adipose tissue (AT) from obese human subjects and correlated with AT inflammation and insulin resistance. 54 By using whole body TSP1-deficient mice, studies from our laboratory revealed a novel role for TSP1 in stimulating macrophage recruitment and activation in AT that contributes to inflammation and insulin resistance resulting from high-fat diet-induced obesity, 33 which was supported by two later reports. 55, 56 Moreover, we found that TSP1 deficiency also protected mice from obesity-induced kidney inflammation and damage in a diet-induced obesity model. 57 Importantly, these protective effects of TSP1 deficiency were observed even though TSP1-deficient mice showed similar levels of obesity as wild-type controls. 33 Moreover, in our unpublished results, we found that TSP1 deficiency reduced lipid accumulation as well as tumor necrosis factor-α production in liver from high-fat diet-fed mice, suggesting that TSP1 stimulates liver steatosis and steatohepatitis and plays a role in NAFLD (Fig. 2) . This hypothesis is supported by a study showing that, in an in vitro NAFLD model, free fatty acid treatment induced TSP1 expression in hepatocytes, which was associated with fat accumulation and inflammatory and fibrogenic responses in these cells. 42 In addition, aerobic swimming training prevented high-fat diet-induced NAFLD in a mouse model throught regulation of lipid metabolism in liver such as downregulation of TSP1 receptor CD36 expression in liver. 58 However, the detailed cellular and molecular mechanims of the involvement of TSP1 in NAFLD are not clear and need further extensive studies.
ROLE OF TSP1 IN LIVER FIBROSIS
L IVER FIBROSIS IS a dynamic wound-healing response of the liver to many causes of chronic injuries including viral infection, alcohol, or NAFLD. It is a complex event involving inflammatory damage, ECM deposition, hepatocyte death, the progressive fibrosis, and remodeling. [59] [60] [61] Classically, the activation and proliferation of HSCs, which represent the major ECMproducing cells, play a key role in liver fibrosis. In addition to HSCs, other cell types in the liver such as immune cells, sinusoidal endothelial cells, and hepatocytes also participate in this process by responding to several key cytokines. 62 These cytokines include TGF-β, platelet-derived growth factor, vascular endothelial growth factor A (VEGFA), connective tissue growth factor, and nerve growth factor. 42 Among these cytokines, the pro-fibrotic effect of TGF-β has been very well studied. Transforming growth factor-β induces HSC activation to transform to the myofibroblast phenotype to produce more collagen, leading to liver fibrosis.
63
Transforming growth factor-β is secreted by many cell types as a latent form. It must be activated before it can elicite its cellular functions. Many factors can activate latent TGF-β. 64 Thrombospondin 1 is an endogenous activator that induces latent TGF-β activation through its type 1 repeat domain (KRFK sequence). 23 Moreover, LSKL peptide has been identified as a TSP1 antagonist to block TSP1-mediated TGF-β activation. 27 This TSP1-mediated TGF-β activation plays an important role in Figure 2 Proposed role of thrombospondin 1 (TSP1) in obesityassociated non-alcoholic fatty liver disease (NAFLD). FFA, free fatty acids; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-α. [Colour figure can be viewed at wileyonlinelibrary.com] tissue injury and fibrosis including diabetes-associated glomerulosclerosis, heart fibrogenic alteration, and liver fibrosis. 25, [65] [66] [67] [68] [69] [70] Increased TSP1 expression and TGF-β levels have been found in the livers of patients with congenital hepatic fibrosis. 41 An in vitro study also showed that TSP1 activates latent TGF-β secreted by HSCs. 71 In addition, bile acid stimulated TSP1 expression in hepatocytes, leading to TGF-β activation, HSC activation, and fibrogenesis. 72 Hepatitis C virus core protein induced intrahepatic TSP1 expression and TGF-β activation in a hepatitis C virus core transgenic mouse model in vivo as well as in the co-culture of hepatoma and stellate cells in vitro. 73 Together, these studies from different disease models suggest that TSP1-mediated TGF-β activation contributes to liver fibrosis. This was further supported by a study showing that injection of the LSKL peptide to block TSP1-mediated TGF-β activation reduced dimethyl-nitrosamine-induced liver damage and fibrosis, 70 suggesting that blocking TSP1-mediated TGF-β activation may serve as a novel therapeutic target for live fibrosis.
59
In addition to its role in mediating TGF-β activation, TSP1 is a known modulator of angiogenesis. 74 Hepatic angiogenesis is closely related to fibrosis in both clinical and experimental conditions. 75 The cross-talk among hepatic sinusoidal endothelial cells, stellate cells, and hepatocytes plays an important role in the angiogenesis process during liver regeneration and fibrosis development. 76 Studies showed that pathological angiogenesis and sinusoidal remodeling may act as the initiators of liver fibrosis 77, 78 and the angiogenesis pathway has been targeted for treatment of liver fibrosis. 59 There is evidence showing that TSP1 correlated with liver angiogenesis in experimental liver fibrosis.
79 Thrombospondin 1 expression in liver was positively correlated with the severity of liver fibrosis as well as angiogenesis in a rat cirrhosis model induced by diethylnitrosamine, 79 suggesting that TSP1 might contribute to liver fibrosis not only as an activator of TGF-β, but also as an modulator of angiogenesis (as illustrated in Fig. 3 ). In addition, studies showed that TSP1, through interaction with its receptor CD47, induces defenestration of liver sinusoidal endothelial cells and contributing to liver fibrogenesis.
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ROLE OF TSP1 IN LIVER CANCER
T HERE ARE VERY limited data on the role of TSP1 in HCC, the third leading form of cancer death worldwide. 81 In human samples, increased TSP1 expression was found in HCC cells and endothelial cells and in fibroblasts surrounding the tumor. Thrombospondin 1 expression was also increased in stromal cells surrounding the tumor. [82] [83] [84] Moreover, studies from Poon et al. indicated that higher TSP1 levels were associated with the presence of venous invasion and advancing tumor staging, and were linked to poor survival in HCC patients. 84 A positive correlation of TSP1 and VEGF levels in HCC was reported in their study, suggesting that TSP1 may stimulate tumor invasion and progression through a pro-angiogenesis role in HCC, similar to that found in pancreatic cancer, 85 colorectal cancer, and cutaneous melanoma. 86, 87 However, this finding is in contrast to the general concept of the antiangiogenesis role of TSP1 played in other types of cancer such as bladder cancer and lung carcinoma. 88, 89 The inhibitory effect of TSP1 on angiogenesis has been shown through either direct regulation of endothelial cell migration, proliferation, and apoptosis or by antagonizing VEGF activity. 13 In addition to TSP1's role in regulating angiogenesis in HCC, interestingly, a recent study by Lee et al. reported that blockade of TSP1 signaling receptor CD47 suppressed HCC growth in vivo through blocking cathepsin-S/protease-activated receptor-2 signaling, 90 suggesting the contribution of increased TSP1 signaling to HCC development and progression. However, there have been some controversial findings. One study found no difference in TSP1 expression between normal and HCC liver samples; 91 another study found that TSP1 levels were greater in normal tissue than in HCC. 92 A further study reported no positive correlation between TSP1 expression levels and tumor grades and angiogenesis in HCC patients. 93 Future studies are needed to solve these discrepancies and further understand the signaling pathways of TSP1 in HCC development and progression. It is a known anti-angiogenesis factor and also a key molecule to activate latent TGF-β. Previous studies indicated that TSP1 is an important player in liver pathophysiology. Future studies are needed to further determine the cellular and molecular mechanisms by which TSP1 contributes to chronic liver diseases. This may lead to the identification of novel therapeutic targets to delay or stop the progression of chronic liver diseases.
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